Zacks: Viking Therapeutics, Inc. (VKTX) Receives Average Rating of “Strong Buy” from Brokerages
Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) have been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price objective of $7.06 for the company and are anticipating that the company will post ($0.23) EPS for the current quarter, according to Zacks. Zacks has also assigned Viking Therapeutics an industry rank of 100 out of 265 based on the ratings given to related companies.
Separately, Maxim Group set a $5.00 price objective on Viking Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 25th.
Shares of Viking Therapeutics (NASDAQ:VKTX) opened at 1.56 on Tuesday. Viking Therapeutics has a 52-week low of $0.90 and a 52-week high of $2.89. The company’s 50-day moving average price is $1.41 and its 200-day moving average price is $1.26. The stock’s market cap is $31.47 million.
“Zacks: Viking Therapeutics, Inc. (VKTX) Receives Average Rating of “Strong Buy” from Brokerages” was posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at http://www.dailypolitical.com/2017/02/16/zacks-viking-therapeutics-inc-vktx-receives-average-rating-of-strong-buy-from-brokerages.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in VKTX. Renaissance Technologies LLC boosted its position in Viking Therapeutics by 666.2% in the fourth quarter. Renaissance Technologies LLC now owns 163,200 shares of the company’s stock valued at $194,000 after buying an additional 141,900 shares during the last quarter. GRT Capital Partners L.L.C. boosted its position in Viking Therapeutics by 187.8% in the fourth quarter. GRT Capital Partners L.L.C. now owns 94,978 shares of the company’s stock valued at $113,000 after buying an additional 61,978 shares during the last quarter. Finally, Sio Capital Management LLC boosted its position in Viking Therapeutics by 53.3% in the third quarter. Sio Capital Management LLC now owns 849,905 shares of the company’s stock valued at $1,191,000 after buying an additional 295,523 shares during the last quarter. 5.97% of the stock is owned by institutional investors.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.